TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00932438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LC beads loaded with Irinotecan
Description: Chemoembolization using LC beads loaded with 100mg Irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/sqm, IV infusion every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/sqm, IV infusion every two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Leucovorin 200 mg/sqm, IV infusion every two weeks
Study: NCT02740712

Intervention type: DRUG
Group type: OTHER
Intervention: Caffeine
Description: 200 mg (4 x 50mg) Tablet
Study: NCT00932438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 200 mg/sqm, IV infusion every two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg given at the discretion of the treating physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg given at the discretion of the treating physician
Study: NCT02403063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Administration of neostigmine 50µg/kg for enhanced recovery after neuromuscular blockade with rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine-sugammadex
Description: Administration of neostigmine 50µg/kg followed 3 minutes later by administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
Study: NCT02833584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol 500 mg x 1 tablets according to patient's body weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 500 mg x 1 tablets according to patient's body weight
Study: NCT00982046

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free RepleniSH multi-purpose disinfecting solution
Description: Contact lens solution CE-marked for intended use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free RepleniSH multi-purpose disinfecting solution
Description: Contact lens solution CE-marked for intended use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free RepleniSH multi-purpose disinfecting solution
Description: Contact lens solution CE-marked for intended use.
Study: NCT03524898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: 150 mg/m2 / 125 mg/m2
Study: NCT02740712

Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin
Description: 10 mg (2 x 5mg) Tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole
Description: 40 mg Tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: 5 mg/mL

Intervention type: DRUG
Group type: OTHER
Intervention: digoxin
Description: .25 mg Tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin K
Description: 10 mg Tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Rucaparib
Description: 200 \& 300 mg tablet
Study: NCT02774044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadisurf
Description: Cadisurf Intratracheal suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural lung extract containing phospholipids and surfactant-associated proteins. The resulting composition provides 25 mg/mL phospholipids and less than 1.0 mg/ml protein. It is suspended in 0.9% sodium chloride solution. Cadisurf contains no preservatives. Each ml of Cadisurf contains 25 mg of phospholipids. It is a creamy white suspension supplied in single-use glass vials containing 8 mL (200 mg phospholipids).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Survanta
Study: NCT04062799

Intervention type: OTHER
Intervention: no intervention
Description: It is an observationa study. There is no intervention.
Study: NCT03524898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 mg/m2
Study: NCT00982046

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus multi-purpose solution
Description: Contact lens solution CE-marked for intended use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus multi-purpose solution
Description: Contact lens solution CE-marked for intended use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus multi-purpose solution
Description: Contact lens solution CE-marked for intended use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care cleaning and disinfecting system
Description: Contact lens care system CE-marked for intended use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care cleaning and disinfecting system
Description: Contact lens care system CE-marked for intended use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care cleaning and disinfecting system
Description: Contact lens care system CE-marked for intended use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon A contact lens (ACUVUE OASYS)
Description: Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B contact lens (AIR OPTIX AQUA)
Description: Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lens (Biofinity)
Description: Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
Study: NCT01808638

Intervention type: DRUG
Group type: OTHER
Intervention: Atu027 & gemcitabine in lead in safety period
Description: Subjects will be treated in a 28-day cycle with Atu027 twice weekly for 4 weeks and gemcitabine once weekly for the first three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atu027 & gemcitabine in treatment arm 1
Description: Subjects will be treated in a 28-day cycle with Atu027 and gemcitabine once weekly for three consecutive weeks (on days 1, 8, and 15). During week four no treatment is administered.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atu027 & gemcitabine in treatment arm 2
Description: Subjects will be treated in a 28-day cycle with gemcitabine once weekly (on days 4, 11, and 18) and Atu027 twice weekly (on days 1, 4, 8, 11, 15, 18, 22, and 25). The 28-day combination cycle is followed by a 28-day gemcitabine monotherapy cycle.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs.
Study: NCT00876096

Intervention type: OTHER
Group type: OTHER
Intervention: Catch of blood then PCR
Description: To optimize the technology of extraction of nucleic acids of origin fongique by collaborating with the laboratories of Parasitologie and Mycology of the TEACHING HOSPITAL of Rennes and Toulouse.
Study: NCT01976546

Intervention type: DEVICE
Intervention: Intubation with mcgrath videolaryngoscope and Boedeker intubation foreceps
Description: Patients will be intubated with the Mcgrath videolaryngoscope and a tracheal tube placed by Boedeker intubation foreceps
Study: NCT03414203

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Transcranial Current Stimulation equipment consists of an ammeter (measured with current intensity), a potentiometer (voltage controller between the electrodes), a generator (two 9-volt batteries) and two electrodes (anode and cathode). The direct low-amplitude currents released by the electrodes reach the cortex and modify the neuronal potentials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial Current Stimulation equipment consists of an ammeter (measured with current intensity), a potentiometer (voltage controller between the electrodes), a generator (two 9-volt batteries) and two electrodes (anode and cathode). The direct low-amplitude currents released by the electrodes reach the cortex and modify the neuronal potentials.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Transcranial Current Stimulation equipment consists of an ammeter (measured with current intensity), a potentiometer (voltage controller between the electrodes), a generator (two 9-volt batteries) and two electrodes (anode and cathode). The direct low-amplitude currents released by the electrodes reach the cortex and modify the neuronal potentials.
Study: NCT01441947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Part of combination arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: part of combination arm
Study: NCT02665663

Intervention type: DEVICE
Group type: OTHER
Intervention: medical device

Intervention type: DEVICE
Group type: OTHER
Intervention: medical device

Intervention type: DEVICE
Group type: OTHER
Intervention: medical device
Study: NCT02473094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 825mg/m2 bid, D1-D5 q7d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 825mg/m2 bid, D1-D5 q7d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin up to 2500mg/d

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 3D radiotherapy 50,4Gy divided in 25 fractions

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: 3D radiotherapy 50,4Gy divided in 25 fractions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo up to 2500mg/d
Study: NCT03092999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg tablet, single dose, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg tablet, single dose, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg tablet, single dose, oral administration
Study: NCT01221623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AA4500
Description: 2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
Study: NCT04031898

Intervention type: OTHER
Intervention: Non Interventional
Description: This is a non interventional, observational, retrospective study including patients with EGFR-mutated advanced NSCLC, treated with 1st or 2nd generation EGFR TKI therapy in first line
Study: NCT04550208

Intervention type: OTHER
Intervention: 3D analysis of different landing tasks
Description: General as well as more sport-specific landing tasks are investigated with 3D analysis by using an opto-electronic system
Study: NCT04185545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus RV3 Vaccine (Bio Farma)
Description: Each 1 mL dose of the final product of oral liquid rotavirus vaccine contains \> 5x10\^6 fcfu/mL rotavirus vaccine strain RV3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus RV3 Vaccine (Bio Farma)
Description: Each 1 mL dose of the final product of oral liquid rotavirus vaccine contains \> 5x10\^6 fcfu/mL rotavirus vaccine strain RV3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus RV3 Vaccine (Bio Farma)
Description: Each 1 mL dose of the final product of oral liquid rotavirus vaccine contains \> 5x10\^6 fcfu/mL rotavirus vaccine strain RV3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus RV3 Vaccine (Bio Farma)
Description: Each 1 mL dose of the final product of oral liquid rotavirus vaccine contains \> 5x10\^6 fcfu/mL rotavirus vaccine strain RV3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each 1 mL dose of placebo contains 30% of sucrose in DMEM

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each 1 mL dose of placebo contains 30% of sucrose in DMEM
Study: NCT03421665

Intervention type: DEVICE
Intervention: Titan 3D Wedge System
Description: Each subject will undergo an LCL procedure and/or medial cuneiform osteotomy with one or more TITAN 3-D™ Wedges. Ancillary fixation should be used in conjunction with each TITAN 3-D™ Wedge used. This surgical procedure will be performed as standard of care and is not part of the research procedures. Post-operative care and weight-bearing/activity restrictions will be at the discretion of the surgeon as part of their standard of care for the procedure.
Study: NCT00294437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zometa
Description: Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
Study: NCT02458040

Intervention type: DRUG
Intervention: Drug selected in the study

Intervention type: DRUG
Intervention: Drug selected in the study

Intervention type: DRUG
Intervention: Drug selected in the study
Study: NCT03618498

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ILM flaps insertion techniques or free ILM flaps.
Description: The ILM flap anchoring on the hole edge was inverted and covered the hole.Otherwise, temporal side ILM flap was used. However, if the risk of ILM flipping back was judged to be high, ILM insertion instead of ILM hole coverage was adopted.If the size of the ILM flaps was judged inadequate, the double ILM insertion technique was used, done by adding a piece of previously obtained free ILM flap on top of the inverted ILM tissue until they were securely in place.
Study: NCT03672669

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Platelet Rich Fibrin (A-PRF)
Description: blood samples collected in 10 ml of vacuumed plain glass tubes were centrifuged for 14 minutes at 1500 rpm without anticoagulant agents in order to obtain A-PRF

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Leukocyte- and platelet-rich fibrin (L-PRF)
Description: blood samples collected in 10 ml of glass coated plastic tubes were centrifuged without anticoagulant agents for 10 minutes in order to obtain L-PRF
Study: NCT01847079

Intervention type: OTHER
Group type: OTHER
Intervention: Procalcitonin
Description: Procalcitonin to guide obtaining bloodcultures
Study: NCT02082028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BGStar

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: glucose meter
Study: NCT04227210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine MV-012-968 (dosage #1)
Description: Single dose administered intranasally on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine MV-012-968 (dosage #2)
Description: Single dose administered intranasally on Day 1
Study: NCT02130570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Model Intensive Discharge Intervention
Description: 1. Inpatient medication safety interventions~2. Inpatient discharge advocate~3. Structured visiting nurse (VNA) appointments~4. Post-discharge phone call by primary care personnel within 2 business days of discharge~5. Structured post-discharge clinic appointment with PCP and other PCMH personnel within 2 weeks of discharge~6. Improved communication between inpatient and primary care teams~7. High-risk patients will receive additional interventions as needed:~   1. Home pharmacist visit~  2. Enrollment in the Partners integrated Care Management Program (iCMP)~  3. Enrollment in telemedicine programs for patients with CHF~  4. Palliative care consultation regarding goals of care~8. Novel health information technology to facilitate communication and transfer of clinical information
Study: NCT02004210

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial radioembolization (TARE)
Description: transarterial radioembolization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization (TACE)
Description: transarterial chemoembolization
Study: NCT04982809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone, Dexamethasone, Prednisolone
Description: Corticosteroids
Study: NCT02840942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Robot
Description: Socially assistive robot MAKI will interact with children via tablet game designed to teach coping skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-coping Robot
Description: Socially assistive robot MAKI will interact with children via tablet game designed to be distraction only.
Study: NCT00861692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: argatroban
Study: NCT03450343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral azacitidine
Description: Azacitidine can be taken with or without food at the same time every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-ICE
Description: R-ICE is approved for the treatment of NHL before ASCT for relapsed or primary refractory diffuse large b-cell lymphoma. R-ICE consists of rituximab, etoposide, carboplatin and ifosfamide. R-ICE will be administered per institutional guidelines.
Study: NCT03644225

Intervention type: DEVICE
Group type: OTHER
Intervention: Measurment with Aspirational Medical Device
Description: The mechanical properties of healthy and SSc-diseased skin will be assessed by suction based measurements with a new developed Aspirational Medical Device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Measurment with Aspirational Medical Device
Description: The mechanical properties of healthy and SSc-diseased skin will be assessed by suction based measurements with a new developed Aspirational Medical Device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Measurment with Cutometer MPA 580
Description: The mechanical properties of healthy and SSc-diseased skin will be assessed by CE-marked Cutometer MPA 580

Intervention type: DEVICE
Group type: OTHER
Intervention: Measurment with Cutometer MPA 580
Description: The mechanical properties of healthy and SSc-diseased skin will be assessed by CE-marked Cutometer MPA 580
Study: NCT04982809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone, Dexamethasone, Prednisolone
Description: Corticosteroids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone, Dexamethasone, Prednisolone
Description: Corticosteroids
Study: NCT01063062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenous infusion every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: methotrexate as per standard of care in clinical practice.
Study: NCT03137680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Exercise
Description: Exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of six weeks.
Study: NCT00136695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: 1 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: anastrozole
Description: 1 mg QD
Study: NCT02195700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-809
Description: SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
Study: NCT04564937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT510A
Description: SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT510A
Description: SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT510A
Description: SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT510A
Description: SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT
Study: NCT01348503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Escalating doses starting at 15 mg by mouth per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Fixed dose of 400 mg by mouth twice a day.
Study: NCT03424863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Muscle Strengthening
Description: 1 session of lower extremity muscle strengthening at moderate intensity (60% of estimated maximal muscle strength). The exercise is performed on one single day.
Study: NCT02195700

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken twice daily for 12 weeks.
Study: NCT03626064

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking Cessation Counselling
Description: One on one smoking cessation counselling with a certified mental health nurse

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine Replacement Therapy
Description: Access to a range of nicotine replacement therapy: nicotine patch, nicotine gum, nicotine lozenge, nicotine inhaler
Study: NCT01320852

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PET Scan
Description: All patients will have a PET scan as part of their pre-transplant assessment

Intervention type: OTHER
Group type: OTHER
Intervention: PET Scan
Description: All patients will have a PET scan as part of their pre-transplant assessment